Korro Bio(KRRO) - 2024 Q3 - Quarterly Results

Exhibit 99.1 Korro Reports Third Quarter 2024 Financial Results and Provides Business Updates — Submitted regulatory filing for first-in-human clinical study of KRRO-110 in patients with alpha-1 antitrypsin deficiency (AATD) — Formed Clinical Advisory Board (CAB) of leading lung and liver experts and strengthened leadership team — Partnered with Novo Nordisk to develop up to two targets for cardiometabolic diseases leveraging Korro's proprietary OPERATM platform — Ended third quarter of 2024 with $169.1 mil ...